CD274 and non-small cell lung carcinoma: In first-line therapies for advanced NSCLC, ICIs as monotherapy, such as pembrolizumab and atezolizumab, have demonstrated clinical benefits primarily in patients with high tumor PD-L1 expression (2, 3).